


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A compound of the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



wherein

R<sup>1</sup> is hydrogen,

R<sup>2</sup> is hydrogen or C<sub>1-20</sub>-alkyl,

R<sup>3</sup> is hydrogen, C<sub>1-20</sub>-alkyl, C<sub>4-8</sub>-cycloalkyl, C<sub>5-8</sub>-cycloalkylenyl, aryl, C<sub>1-20</sub>-alkoxy, or a group of formula -W-R<sup>8</sup>[. . .];

R<sup>3a</sup> is hydrogen or C<sub>1-20</sub>-alkyl,

R<sup>4</sup> is hydrogen,

R<sup>5</sup> is hydrogen; nitro; halogen or trifluoromethyl; azido; cyano; S-C<sub>1-4</sub>-alkyl; SO-C<sub>1-4</sub>-alkyl; SO<sub>2</sub>-C<sub>1-4</sub>-alkyl; SONH<sub>2</sub>; C<sub>1-20</sub>-alkyl unsubstituted or substituted by halogen; or C<sub>1-20</sub>-alkoxy unsubstituted or substituted by halogen,

R<sup>6</sup> is hydrogen, C<sub>1-20</sub>-alkyl or halogen,


R<sup>7</sup> is hydrogen, C<sub>1-20</sub>-alkyl or halogen,

W is C<sub>1-12</sub>-alkylene, -NH- or -NHC(=O)-, and

R<sup>8</sup> is aryl.

and at least one of R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> is different from hydrogen when R<sup>2</sup> is hydrogen, R<sup>3</sup> is H or 2, 6-diisopropylphenyl, and R<sup>3a</sup> is H.

2. (Currently amended) A compound of the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



wherein

R<sup>1</sup> is hydrogen,

R<sup>2</sup> is hydrogen or C<sub>1-4</sub>-alkyl,

R<sup>3</sup> is hydrogen; C<sub>1-6</sub>-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl and alkylamino; C<sub>5-7</sub>-cycloalkyl; (hydroxymethyl) cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C<sub>1-4</sub>-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, and trifluoromethylthio; or a group of formula W-R<sup>8</sup>,

R<sup>3a</sup> is hydrogen, C<sub>1-4</sub>-alkyl,

R<sup>4</sup> is hydrogen,

R<sup>5</sup> is hydrogen; nitro; halogen or trifluoromethyl; C<sub>1-4</sub>-alkyl, unsubstituted or substituted by halogen; or C<sub>1-4</sub>-alkoxy unsubstituted or substituted by halogen,

R<sup>6</sup> is hydrogen, C<sub>1-6</sub>-alkyl or halogen,


R<sup>7</sup> is hydrogen, methyl or halogen,

W is C<sub>1-4</sub>-alkylene unsubstituted or substituted by halogen, hydroxy, C<sub>1-4</sub>-alkyl or alkoxy; -NH-; or -NHC(=O)-, and

R<sup>8</sup> is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C<sub>1-4</sub>-alkyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluoromethylthio;

and at least one of R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> is different from hydrogen when R<sup>2</sup> is hydrogen, R<sup>2</sup> is H or 2,6-diisopropylphenyl, and R<sup>3a</sup> is H.

3. (Currently amended) A compound of the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



wherein

R<sup>1</sup> is hydrogen,

R<sup>2</sup> is hydrogen, methyl or ethyl,

R<sup>3</sup> is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, 1-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dimethylamino)propyl, 6-(hydroxymethyl)cyclohex-3-en-1-yl, 3-hydroxyphenyl, 3-fluorophenyl, 3-(2-pyridin-2-ylethyl) phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro-6-fluorobenzyl, 2-[(trifluoromethyl) thio] benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, [4-bromophenyl]amino, or methoxy,

R<sup>3a</sup> is hydrogen, methyl,

R<sup>4</sup> is hydrogen,

R<sup>5</sup> is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen,

R<sup>6</sup> is hydrogen, methyl or Cl, and

R<sup>7</sup> is hydrogen, methyl, Br, F or Cl;

and at least one of R<sup>5</sup>, R<sup>6</sup> or R<sup>7</sup> is different from hydrogen when R<sup>2</sup> is hydrogen, R<sup>3</sup> is H or 2,6-diisopropylphenyl and R<sup>3a</sup> is H.

4. (previously presented) A compound according to claim 1 wherein R<sup>2</sup> is hydrogen or methyl.
5. (previously presented) A compound according to claim 1 wherein R<sup>3</sup> is hydrogen.
6. (previously presented) A compound according to claim 1 wherein R<sup>3a</sup> is hydrogen.
7. (Canceled)

8. (previously presented) A compound according to claim 1 wherein R<sup>6</sup> is hydrogen.
9. (previously presented) A compound according to claim 1 wherein R<sup>7</sup> is hydrogen, Br, or F.
10. (previously presented) A compound according to claim 1 wherein R<sup>2</sup> is C<sub>1-20</sub>-alkyl and the carbon atom to which R<sup>2</sup> is attached is in the “S”-configuration.
11. (currently amended) A compound selected from  
2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5,7-dibromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-nitro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
(2R)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
(2S)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
2-[2-oxo-5-(fluoromethoxy)-2,3-dihydro-1H-indol-1-yl]acetamide;  
2-(5-isopropyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-ethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5,7-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(2-oxo-5-propyl-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(2-oxo-5-(trifluoromethyl)-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5,6-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(7-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(6-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;  
(+)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;  
(-)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;  
2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
(+)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;

(-)2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
(-)2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
(+)-2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;  
2-(5-chloro-7-fluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxyphenyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-fluorophenyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(4-hydroxy-3-methoxybenzyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[4-(methylsulfonyl)benzyl]acetamide;  
N'-(4-bromophenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetohydrazide;  
N-butyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxypropyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(dimethylamino)propyl]acetamide;  
ethyl{[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]amino}acetate;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-ethoxypropyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-fluoroethyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methoxy-N-methylacetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dimethylphenyl)acetamide;  
N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxy-2,2-dimethylpropyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[1-(hydroxymethyl)propyl]acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-hydroxy-2-phenylethyl)acetamide;  
2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide;

2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-chlorophenylethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(4-methylphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-nitrobenzyl)acetamide; N-(2-chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide; N-benzyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-{2-[(trifluoromethyl) thio] benzyl}acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-cycloheptylacetamide; and pharmaceutically acceptable salts thereof.

12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.
- 19.-21. (canceled)